Resveratrol induces apoptosis of human chronic myelogenous leukemia cells in vitro through p38 and JNK-regulated H2AX phosphorylation

Acta Pharmacologica Sinica

Volumn 36, Issue 3, 2015, Pages 353-361

  Wu, Xin Pin ^a,b   Xiong, Min ^b   Xu, Cheng Shan ^b   Duan, Lian Ning ^b   Dong, Ya Qiong ^a   Luo, Yuan ^b   Niu, Tian Hui ^b   Lu, Cheng Rong ^a,b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b AIR FORCE GENERAL HOSPITAL   (China)

Author keywords

Apoptosis; Chronic myelogenous leukemia; H2AX; JNK; K562 cell; P38; Resveratrol; SB202190; SiRNA; SP600125

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; HISTONE H2AX; HISTONE H3; JANUS KINASE; LENTIVIRUS VECTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; RESVERATROL; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TUMOR SUPPRESSOR PROTEIN; ANTINEOPLASTIC AGENT; H2AFX PROTEIN, HUMAN; HISTONE; PROTEIN KINASE INHIBITOR; STILBENE DERIVATIVE; STRESS ACTIVATED PROTEIN KINASE;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CHRONIC MYELOID LEUKEMIA; DOSE RESPONSE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; K562 CELL LINE; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; K-562 CELL LINE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; TIME FACTOR;

ANTINEOPLASTIC AGENTS; APOPTOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; HISTONES; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STILBENES; TIME FACTORS; TRANSFECTION;

EID: 84938487604     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2014.132     Document Type: Article

References (29)

1. Goldman JM, Melo JV. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med 2003;349:1451-64.
2. Goldman JM, Melo JV. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1084-6.
3. Dumka D, Puri P, Carayol N, Lumby C, Balachandran H, Schuster K, et al. Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib. Leuk Lymphoma 2009;50:2017-29.
4. Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, Benet I, et al. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med 2000;191:977-84.
5. Branford S, Yeung DT, Parker WT, Roberts ND, Purins L, Braley JA, et al. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood 2014;124:511-8.
6. Chu S, Holtz M, Gupta M, Bhatia R. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood 2004;103:3167-74.
7. Lu Z, Jin Y, Chen C, Li J, Cao Q, Pan J. Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl. Mol Cancer 2010;9:112.
8. Mesa RA. Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders. Biologics 2007;1:129-38.
9. Deguchi Y, Kimura S, Ashihara E, Niwa T, Hodohara K, Fujiyama Y, et al. Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leuk Res 2008;32:980-3.
10. Nicolini FE, Ibrahim AR, Soverini S, Martinelli G, Muller MC, Hochhaus A, et al. The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica 2013;98:1510-6.
11. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003;101:690-8.
12. Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D, et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004;36:453-61.
13. Athar M, Back JH, Tang X, Kim KH, Kopelovich L, Bickers DR, et al. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 2007;224:274-83.
14. Li F, Gong Q, Dong H, Shi J. Resveratrol, a neuroprotective supplement for Alzheimer's disease. Curr Pharm Des 2012;18:27-33.
15. Shen M, Jia GL, Wang YM, Ma H. Cardioprotective effect of resvaratrol pretreatment on myocardial ischemia-reperfusion induced injury in rats. Vascul Pharmacol 2006;45:122-6.
16. Park SJ, Ahmad F, Philp A, Baar K, Williams T, Luo H, et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 2012;148:421-33.
17. Puissant A, Grosso S, Jacquel A, Belhacene N, Colosetti P, Cassuto JP, et al. Imatinib mesylate-resistant human chronic myelogenous leukemia cell lines exhibit high sensitivity to the phytoalexin resveratrol. Faseb J 2008;22:1894-904.
18. Surh YJ, Hurh YJ, Kang JY, Lee E, Kong G, Lee SJ. Resveratrol, an antioxidant present in red wine, induces apoptosis in human promyelocytic leukemia (HL-60) cells. Cancer Lett 1999;140:1-10.
19. Whyte L, Huang YY, Torres K, Mehta RG. Molecular mechanisms of resveratrol action in lung cancer cells using dual protein and microarray analyses. Cancer Res 2007;67:12007-17.
20. Li T, Wang W, Li T. Antileukemic mechanism of resveratrol in vitro and in mice bearing L1210-tumor. Zhong Xi Yi Jie He Xue Bao 2008;6:1267-74.
21. Dorrie J, Gerauer H, Wachter Y, Zunino SJ. Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Cancer Res 2001;61:4731-9.
22. Puissant A, Robert G, Fenouille N, Luciano F, Cassuto JP, Raynaud S, et al. Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation. Cancer Res 2010;70:1042-52.
23. Liu Y, Tseng M, Perdreau SA, Rossi F, Antonescu C, Besmer P, et al. Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate. Cancer Res 2007;67:2685-92.
24. Zhang YJ, Lu CR, Cao Y, Luo Y, Bao RF, Yan S, et al. Imatinib induces H2AX phosphorylation and apoptosis in chronic myelogenous leukemia cells in vitro via caspase-3/Mst1 pathway. Acta Pharmacol Sin 2012;33:551-7.
25. Dong Y, Xiong M, Duan L, Liu Z, Niu T, Luo Y, et al. H2AX phosphorylation regulated by p38 is involved in Bim expression and apoptosis in chronic myelogenous leukemia cells induced by imatinib. Apoptosis 2014;19:1281-92.
26. Lu C, Zhu F, Cho YY, Tang F, Zykova T, Ma WY, et al. Cell apoptosis: requirement of H2AX in DNA ladder formation, but not for the activation of caspase-3. Mol Cell 2006;23:121-32.
27. Lu C, Xiong M, Luo Y, Li J, Zhang Y, Dong Y, et al. Genome-wide transcriptional analysis of apoptosis-related genes and pathways regulated by H2AX in lung cancer A549 cells. Apoptosis 2013;18:1039-47.
28. Milella M, Kornblau SM, Estrov Z, Carter BZ, Lapillonne H, Harris D, et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 2001;108:851-9.
29. Banerjee Mustafi S, Chakraborty PK, Raha S. Modulation of Akt and ERK1/2 pathways by resveratrol in chronic myelogenous leukemia (CML) cells results in the downregulation of Hsp70. PLoS one 2010;5:e8719.